NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis $1.49 -0.05 (-3.25%) Closing price 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.34%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aclaris Therapeutics Stock (NASDAQ:ACRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aclaris Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.5950-Day Range$1.48▼$2.5752-Week Range$0.95▼$5.17Volume805,468 shsAverage Volume1.17 million shsMarket Capitalization$160.80 millionP/E RatioN/ADividend YieldN/APrice Target$11.67Consensus RatingBuy Company OverviewAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More… Remove Ads Aclaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreACRS MarketRank™: Aclaris Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 604th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aclaris Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aclaris Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.02% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 26.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.02% of the float of Aclaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Aclaris Therapeutics has recently increased by 26.68%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.63 News SentimentAclaris Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aclaris Therapeutics' insider trading history. Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Stock News HeadlinesAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 26.7% in MarchApril 1 at 2:47 AM | americanbankingnews.comAclaris Therapeutics assumed with an Overweight at Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.April 3, 2025 | American Alternative (Ad)Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform RecommendationMarch 8, 2025 | msn.comAclaris Therapeutics initiated with an Outperform at ScotiabankMarch 8, 2025 | markets.businessinsider.comThis Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last YearMarch 5, 2025 | uk.finance.yahoo.comAclaris Therapeutics to Participate in Two March Healthcare ConferencesMarch 4, 2025 | globenewswire.comAclaris Therapeutics files $300M mixed securities shelfFebruary 28, 2025 | markets.businessinsider.comSee More Headlines ACRS Stock Analysis - Frequently Asked Questions How have ACRS shares performed this year? Aclaris Therapeutics' stock was trading at $2.48 at the beginning of the year. Since then, ACRS shares have decreased by 39.9% and is now trading at $1.49. View the best growth stocks for 2025 here. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The biotechnology company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 136.65%. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/06/2024Today4/03/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRS CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees100Year Founded2012Price Target and Rating Average Stock Price Target$11.67 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+675.2%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-136.65% Pretax Margin-138.00% Return on Equity-40.26% Return on Assets-31.71% Debt Debt-to-Equity RatioN/A Current Ratio7.03 Quick Ratio7.03 Sales & Book Value Annual Sales$18.72 million Price / Sales8.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.68Miscellaneous Outstanding Shares107,919,000Free Float66,859,000Market Cap$162.42 million OptionableOptionable Beta0.53 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:ACRS) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.